With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products. Among these, we propose to incentivize gene therapy companies to adopt a status that translates their corporate social responsibility into concrete commitments.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
High, K. A. & Roncarolo, M. G. N. Engl. J. Med. 381, 455–464 (2019).
Marsden G., Towse, A., Pearson, S. D., Dreitlin, B. & Henshall, C. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value https://icer-review.org/material/white-paper-gene-therapy (2017).
Bach, P. B. ‘Anchoring’ was at work in setting the price of Novartis’ new gene therapy. STAT https://www.statnews.com/2019/06/04/anchoring-price-zolgensma (2019).
Brody, B. The Hastings Center Report 26, 5–11 (1996).
World Health Organization. Improving the Transparency of Markets for Medicines, Vaccines, and Other Health Products [footnote]. https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf (2019).
Cummings, B. Columbia Law Rev. 112, 578–627 (2012).
Business Roundtable. Our Commitment. https://opportunity.businessroundtable.org/ourcommitment (2019).
The authors declare no competing interests.
About this article
Cite this article
Fischer, A., Dewatripont, M. & Goldman, M. Benefit Corporation: a path to affordable gene therapies?. Nat Med 25, 1813–1814 (2019). https://doi.org/10.1038/s41591-019-0676-z
This article is cited by
Nature Reviews Immunology (2023)
Nature Reviews Drug Discovery (2023)
Nature Medicine (2023)